People · Operator
Named in public records as an officer, director or promoter · active 2015–2025 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Arcellx, Inc. | — | Biotechnology | Series D+ | $272.8M | $1.8B | 2019 |
| Avalyn Pharma Inc. | — | Biotechnology | Series D+ | $244.0M | $2.7B | 2023 |
| Spruce Biosciences, Inc. | — | Biotechnology | Series C | $191.6M | $274.5M | 2020 |
| Mirum Pharmaceuticals, Inc. | — | Pharmaceuticals | Series C | $138.5M | $348.3M | 2018 |
| Aristea Therapeutics, Inc. | — | Biotechnology | Series C | $63.1M | $2.3B | 2020 |
| Anaptysbio Inc | — | Pharmaceuticals | Series C | $50.8M | $1.4B | 2015 |
| Rezo Therapeutics, Inc. | — | Biotechnology | Series C | $46.3M | $868.3M | 2022 |
| Nkarta, Inc. | — | Biotechnology | Series C | $43.9M | $1.8B | 2019 |
| Ray Therapeutics, Inc. | — | Biotechnology | Series A | $20.0M | $126.9M | 2023 |
Tiba Aynechi at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Tiba Aynechi on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Ali Behbahani | 2 | 17 |
| Jonathan Leff | 2 | 11 |
| Michael Grey | 2 | 10 |
| Niall O'Donnell | 2 | 7 |
| Jill Carroll | 2 | 4 |
| James Topper | 1 | 12 |
| Ed Mathers | 1 | 11 |
| Patrick Heron | 1 | 11 |
| Ketan Patel | 1 | 10 |
| Heath Lukatch | 1 | 10 |
| Simeon George | 1 | 8 |
| Fouad Azzam | 1 | 8 |
| Vineeta Agarwala | 1 | 8 |
| Patrick J. Heron | 1 | 7 |
| Carol Gallagher | 1 | 6 |
| Peter Moldt | 1 | 6 |
| James N. Topper | 1 | 5 |
| MICHAEL DYBBS | 1 | 5 |
| Robert Hoffman | 1 | 5 |
| Sean Ainsworth | 1 | 5 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.